BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 199 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q3 2021. The put-call ratio across all filers is 0.63 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $84,373 | -33.2% | 11,917 | -33.6% | 0.00% | – |
| Q2 2023 | $126,262 | -0.7% | 17,935 | +17.6% | 0.00% | – |
| Q1 2023 | $127,160 | -9.4% | 15,247 | +24.8% | 0.00% | – |
| Q4 2022 | $140,286 | +15.0% | 12,220 | +26.0% | 0.00% | – |
| Q3 2022 | $122,000 | +139.2% | 9,700 | +102.8% | 0.00% | – |
| Q2 2022 | $51,000 | -13.6% | 4,783 | +30.3% | 0.00% | – |
| Q1 2022 | $59,000 | -16.9% | 3,672 | -29.1% | 0.00% | – |
| Q4 2021 | $71,000 | +7000.0% | 5,178 | +5718.0% | 0.00% | – |
| Q3 2021 | $1,000 | 0.0% | 89 | 0.0% | 0.00% | – |
| Q2 2021 | $1,000 | 0.0% | 89 | 0.0% | 0.00% | – |
| Q1 2021 | $1,000 | 0.0% | 89 | -13.6% | 0.00% | – |
| Q4 2017 | $1,000 | 0.0% | 103 | -65.8% | 0.00% | – |
| Q2 2016 | $1,000 | 0.0% | 301 | -3.8% | 0.00% | – |
| Q1 2016 | $1,000 | 0.0% | 313 | +172.2% | 0.00% | – |
| Q4 2015 | $1,000 | – | 115 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| VHCP Management, LLC | 1,744,356 | $18,455,000 | 9.59% |
| RA Capital Management | 4,347,456 | $45,996,000 | 3.30% |
| Cormorant Asset Management, LP | 1,168,000 | $12,357,000 | 2.84% |
| Baker Brothers Advisors | 5,867,031 | $62,073,000 | 0.79% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 907,920 | $9,606,000 | 0.39% |
| QVT Financial LP | 525,734 | $5,562,000 | 0.32% |
| EAM Investors, LLC | 114,548 | $1,212,000 | 0.22% |
| FRANKLIN STREET ADVISORS INC /NC | 93,000 | $984,000 | 0.20% |
| THB ASSET MANAGEMENT | 301,529 | $3,190,000 | 0.19% |
| TPG Group Holdings (SBS) Advisors, Inc. | 1,162,269 | $12,297,000 | 0.13% |